Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Clinical trial NCT03944772 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03944772
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2019-06-25
Primary completion: 2025-05-06
Enrollment: 247

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.